Description
PT-141, also known as Bremelanotide, is a synthetic peptide derived from research involving melanocortin receptors. Unlike compounds primarily investigated for peripheral vascular effects, PT-141 has been studied for its interaction with melanocortin receptor pathways within the central nervous system.
Its distinctive mechanism of action has made it a subject of scientific interest in research examining melanocortin signaling, neurobiology, and associated physiological processes.
Research Background
PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It interacts with melanocortin receptors, particularly MC3R and MC4R, which are involved in a variety of physiological signaling pathways.
Researchers have investigated melanocortin receptor activity in relation to:
- Central nervous system signaling
- Melanocortin receptor pharmacology
- Neuroendocrine pathways
- Receptor-mediated physiological responses
PT-141 provides a research model for exploring the biological activity of melanocortin-based compounds and their interactions with specific receptor systems.
Product Information
- Compound: PT-141
- Alternative Name: Bremelanotide
- Compound Class: Synthetic melanocortin peptide analogue
- Research Focus: Melanocortin receptor signaling
- Intended Use: Laboratory research and analytical applications only
Third Party COA
Lab: SideChain Analytics
Date: October 20, 2026
Purity: 99.8%
Mass: 11.66MG
This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.





Reviews
There are no reviews yet.